Tech Company Financing Transactions
Q32 Bio Funding Round
Q32 Bio, based in Cambridge, secured $60 million in funding from Acorn Bioventures, OrbiMed and private investors.
Transaction Overview
Company Name
Announced On
10/30/2020
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Acorn Bioventures (Lead Investor) (Isaac Manke)
OrbiMed (Lead Investor) (Stephen Squinto)
Proceeds Purpose
Proceeds from the Series B financing will support the advancement of ADX-914 through demonstration of proof-of-mechanism and propel the company's groundbreaking tissue-targeted complement regulation platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 11th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Broxson
Chief Scientific Officer
Shelia Violette
Vice President
Susan Kalled
VP - Bus. Development
Maria Marzilli
VP - Manufacturing
Kathryn Golden
VP - Operations
Charles Romano
Browse more venture capital transactions:
Prev: 10/30/2020: Arable venture capital transaction
Next: 10/30/2020: Slingshot Aerospace venture capital transaction
Share this article
About Our VC Transactions Data
We document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs